https://www.businesswire.com/news/home/20180717005095/en/

CHICAGO--(BUSINESS WIRE)--Jul 17, 2018--Salveo Capital, an alternative investment firm specializing in the legalized cannabis space, today announced it has acquired a minority equity interest in PathogenDx, a provider of DNA-based pathogen testing kits for the cannabis, botanical, food and agriculture industries. Financial terms of the transaction were not disclosed.

Founded in 2014, PathogenDx’s mission is to deliver disruptive testing technology and solutions to the cannabis, botanical, food and agricultural testing markets that provide breakthrough simplicity, and cost-effectiveness, at an adaptable scale for both large and small testing facilities. The company’s technology offers growers, processors, producers, consumers and ancillary service providers within the botanical, food and agricultural markets real-time data and information pertaining to the quality of their product. PathogenDx’s testing can be scaled for testing facilities of all sizes from an individual plant to large agricultural fields. PathogenDx’s technology provides customers with access to accurate real-time answers to determine if their plants or crops have been contaminated with fungi, molds, viruses or mildew. The company is headquartered in Tucson, Arizona.